GlassScriptPhysician profile
Heather Banks
NPI 1982884763
$2,458.89
in general payments reported to CMS, 2019-2025
23 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $75.69 · 2021: $320 · 2022: $324 · 2023: $491 · 2024: $412 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $55.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.27 |
| Education | $55.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $403.83 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $286.42 | 2022-2025 | Tavneos, Parsabiv, Aranesp |
| Opko Pharmaceuticals, LLC | $243.15 | 2019-2024 | Rayaldee |
| Ardelyx, INC. | $184.71 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $155.98 | 2019-2024 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $154.16 | 2025 | |
| Vifor Pharma, INC. | $142.84 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $123.19 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $99.79 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.13 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $81.06 | 2024-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $80.43 | 2021 | |
| Glaxosmithkline, LLC. | $60.53 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $58.11 | 2020-2021 | |
| Boston Scientific Corporation | $57.38 | 2024 | Watchman Flx, Avvigo Guidance System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $49.00 | 2023-2024 | Velphoro, Korsuva |
| Travere Therapeutics, INC. | $36.47 | 2019-2025 | Thiola |
| Calliditas Therapeutics US INC. | $31.46 | 2022-2023 | Tarpeyo |
| Horizon Therapeutics Plc | $29.08 | 2020-2023 | Krystexxa |
| Nxstage Medical, INC. | $26.97 | 2021 | |
| Cormedix INC. | $21.28 | 2024 | Defencath |
| Scpharmaceuticals INC. | $17.19 | 2025 | |
| Ani Pharmaceuticals, INC. | $16.73 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Banks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.